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Abstract
Background: The beta-2-Adrenergic receptor (ADRB2) gene on chromosome 5q33.1 is an important
immunoregulatory factor. We and others have previously implicated chromosomal region 5q31-33 for
contribution to the genetic susceptibility to Graves disease (GD) in East-Asian populations. Two recent
studies showed associations between the single nucleotide polymorphism (SNP) rs1042714 in the ADRB2
gene and GD. In this study, we aimed to fully investigate whether the ADRB2 gene conferred susceptibility
to GD in Chinese population, and to perform a meta-analysis of association between ADRB2 and GD.
Methods: Approximately 1 kb upstream the transcription start site and the entire coding regions of the
ADRB2 gene were resequenced in 48 Han Chinese individuals to determine the linkage disequilibrium (LD)
patterns. Tag SNPs were selected and genotyped in a case-control collection of 1,118 South Han Chinese
subjects, which included 428 GD patients and 690 control subjects. A meta-analysis was performed with
the data obtained in the present samples and those available from prior studies.
Results: Fifteen SNPs in the ADRB2 gene were identified by resequencing and one SNP was novel. Ten
tag SNPs were investigated further to assess association of ADRB2 in the case-control collection. Neither
individual tag SNP nor haplotypes showed association with GD in Han Chinese population (P > 0.05). Our
meta-analysis of the ADRB2 SNP rs1042714 measured heterogeneity between the ethnic groups (I2 =
53.1%) and no association to GD was observed in the overall three studies with a random effects model
(OR = 1.13, 95% CI, 0.95 to 1.36; P = 0.18). However, significant association was found from the combined
data of Caucasian population with a fixed effects model (OR = 1.18, 95% CI, 1.06 to 1.32; P = 0.002; I2 =
5.9%).
Conclusion: Our study indicated that the ADRB2 gene did not exert a substantial influence on GD
susceptibility in Han Chinese population, but contributed to a detectable GD risk in Caucasian population.
This inconsistency resulted largely from between-ethnicity heterogeneity.
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Background
Graves disease (GD) affects 0.5–1% of the general popu-
lation[1], and results from the presence of autoantibodies
to the thyroid-stimulating hormone receptor (TSHR),
leading to over-activity of the thyroid gland. Genome-
wide screens conducted in GD have identified a number
of regions of linkage, although independent replication
and novel candidate loci are to be awaited. Our previous
study[2], along with others[3,4], has suggested that chro-
mosomal region 5q31-33 may contain a locus that con-
tributes to the genetic susceptibility to GD in Eastern-
Asian populations. ADRB2, a 1242-base pair intronless
gene, is located on the long arm of chromosome 5q33.1.
At least thirteen SNPs have been identified in the gene
region[5,6]. Two activity-related polymorphisms
(rs1042713 and rs1042714) with high allelic frequency in
the general population are single nucleic acid substitu-
tions at positions 46 (A-G) and 79 (C-G), corresponding
to substitutions of glycine for arginine at amino acid posi-
tion 16 and glutamate for glutamine at amino acid posi-
tion 27[5,6].
Recently, these two SNPs (rs1042713 and rs1042714) and
another SNP located at position -367 (rs11959427) were
reported association with GD in a Polish case-control col-
lection[7]. The result indicated that Gln27 carriers
(rs1042714CC or rs1042714GC genotypes) had
increased risk of GD. Additionally, the genome-wide asso-
ciation study (GWAS) of the Wellcome Trust Case Control
Consortium (WTCCC) et al also showed positive signal in
the ADRB2 gene[8]. Although three SNPs (rs12654778,
rs1042713 and rs1042714) in the ADRB2 gene genotyped
in the study of WTCCC et al. did not meet a point-wise sig-
nificance level of P < 10-3 for the Cochran-Armitage test
for trend, the original analyses showed significant associ-
ation of rs1042713 and rs1042714 to GD (P = 0.04 for
rs1042713 and P = 0.02 for rs1042714).
ADRB2 is a G protein coupled receptor that is expressed
by all lymphoid cells, with the exception of T helper (Th)
2 cells[9]. Norepinephrine and epinephrine, through
stimulation of the ADRB2-cAMP-protein kinase A path-
way, cause a selective suppression of Th1 responses and
cellular immunity, and a Th2 shift toward dominance of
humoral immunity[9]. Moreover, various polymor-
phisms in the ADRB2 gene were demonstrated as leading
to a variation of ADRB2 expression on the cell sur-
face[10,11]. Therefore, the polymorphisms may influence
the activity of ADRB2, and disturb the Th1/Th2 cytokine
balance, which is an important factor in the pathogenesis
of GD. In addition, ADRB2 had been reported association
with another autoimmune disease, rheumatoid arthritis
[12]. This increased the possibility of ADRB2 association
with GD, as different autoimmune diseases may share
similar genetic etiologies. Given its chromosomal loca-
tion within a region of genetic linkage to GD and the role
of ADRB2 on the immune response, the ADRB2  gene
makes a plausible candidate for GD and autoimmunity in
general.
In the present study, we set to determine whether ADRB2
was a susceptibility locus for GD in Han Chinese popula-
tion and conduct a global meta-analysis of the ADRB2 var-
iation association with GD. Firstly, we identified the
variants of ADRB2 by resequencing the 5' flanking region
and the entire coding region; then we defined linkage dis-
equilibrium (LD) among SNPs across the ADRB2
genomic interval, and selected tag SNPs. Secondly, we
conducted a case-control association study (428 GD cases
and 690 controls) using the tag SNPs, which included
three aforementioned polymorphisms. Finally, we per-
formed a meta-analysis combining the result of our




Unrelated southern Han Chinese patients with GD were
recruited from hospitals in Shanghai. The diagnosis of GD
was based on documented clinical and biochemical evi-
dence of hyperthyroidism, diffused goiter, and the pres-
ence of at least one of the following: positive TSH receptor
antibody tests, diffusely increased 131I (iodine-131)
uptake in the thyroid gland, or presence of exophthalmos.
The severity of Graves' ophthalmopathy (GO) was
assessed according to the NOSPECS classification[13].
Information was also collected from examination of med-
ical records and all other available sources. All control
subjects were given tests for thyroid function and autoan-
tibody status, and anyone showing evidence of subclinical
autoimmune thyroid disease (AITD) was removed from
the study. Control subjects with known family history of
autoimmune disease were also excluded.
In total, 428 GD patients and 690 unrelated control sub-
jects were recruited for the case-control study. Of the GD
patients, 132 showed ophthalmopathy defined as ATA
class III or worse and were classified as GO (+). A sample
set of 24 GD cases and 24 controls was used for resequenc-
ing. With informed consent, blood samples were collected
from all the participants for DNA preparation as well as
biochemical measurements. Genomic DNA was isolated
from peripheral blood leukocytes with FlexiGene DNA Kit
(Qiagenn Hilden, Germany). This project was approved
by the Ethical Committee of the Chinese National Human
Genome Center at Shanghai for the involvement of
human subjects.
SNP identification by resequencing
We carried out SNP identification by resequencing a 1050
bp stretch located 5'-upstream of transcription start codon
and the entire coding regions of ADRB2 in 24 patients andBMC Medical Genetics 2009, 10:26 http://www.biomedcentral.com/1471-2350/10/26
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24 control subjects. The sequencing reactions were per-
formed using Applied Biosystems BigDye (version 3.1)
chemistry (Applied Biosystem, Foster City, CA, USA), and
the sequences were resolved using an ABI 3730 Genetic
Analyzer (Applied Biosystem, Foster City, CA, USA). Anal-
yses of the sequence traces were performed using the Sta-
den package[14] and were double scored by a second
operator.
Genotyping
Genotyping for the tag SNPs was performed using TaqMan
chemistry (Applied Biosystem, Foster City, CA, USA). The
TaqMans reaction was carried out following Applied Bio-
systems standard protocol. Fluorescent emissions were cap-
tured using the ABI Prisms 7900HT Sequence Detection
System (Applied Biosystem, Foster City, CA, USA) and con-
verted into genotypes using the ABI Prisms SDS 2.0 soft-
ware package. The data completion rate was 98.5%.
Statistical analysis
We used χ2 analysis to evaluate the significance of differ-
ences in genotype and allele frequencies between cases
and controls. Allele frequencies for cases and controls
were used to calculate the odds ratio (OR) and the 95%
confidence interval (95% CI). The software used for statis-
tical calculations was the SPSS 15.0 (SPSS Inc., Chicago,
IL, USA) unless specified. Genotype distributions in
patients and controls were evaluated for departure from
Hardy-Weinberg equilibrium by the Haploview v4.0 soft-
ware[15]. From the SNPs detected by resequencing, we
selected tag SNPs with a minimum threshold value of 0.8
for the r2 parameter. The tag SNPs were further genotyped
in the collections of 428 GD patients and 690 unrelated
controls. Blocks were determined using the default
method of Gabriel et al[16] and haplotypes frequencies
were estimated using an implementation of the expecta-
tion maximization algorithm by Haploview v4.0. We
tested association with χ2 analysis for each possible com-
bination of haplotypes derived from rs1042713 and
rs1042714 using Haploview v4.0. P-values less than 0.05
were considered statistically significant.
Heterogeneity between studies was evaluated using the I2
statistic for inconsistency[17] and the χ2  distributed
Cochran Q-statistic[18]. I2 is given by 100% × (Q - df)/Q,
where df denotes degrees of freedom. It describes the pro-
portion of variation that is unlikely due to chance and is
considered large for values > 50%[19]. The Q-test is the
most widely used test for heterogeneity, but is recognized
to have poor power when there are few studies. Hence Q
is considered statistically significant for P < 0.10[17,18].
However I2 is unaffected by the number of studies and
consequently is useful when comparing subgroups within
the overall study. The I2 estimate and the Q-statistic were
both computed for comparison. A fixed-effect model
using Mantel-Haenszel method and a random-effects
model using DerSimonian and Laird method were used to
pool the results [20]. Random effects models are more
conservative than fixed effects models and generate a
wider confidence interval. Meta-analysis was performed
using Review Manager software (version 4.2) http://
www.cc-ims.net/RevMan/.
Results
Fifteen polymorphisms were identified through the rese-
quencing of ADRB2 for 48 individuals (Table 1), all of
which were SNPs; one SNP (-332) located at position -332
upstream from the ADRB2 transcription initiation site was
novel when compared with dbSNP Build 128. The non-
synonymous SNP rs1800888 at nt 491 (+491 C→T, 164
Thr→Ile) in the coding region was found not to be poly-
morphic in these 48 Chinese individuals. Among the fif-
teen SNPs, twelve SNPs had minor allele frequencies
(MAF) great than 5% (Table 1), with frequencies ranging
from 5.2% (rs1042711, rs1801704 and rs1042714) to
38.9% (rs1042719). The frequencies of the fifteen SNPs in
48 individuals were in Hardy-Weinberg equilibrium (P >
0.05, Table 1). The linkage disequilibrium (LD) structure
among the SNPs was examined by program Haploview
4.0 (Figure 1). The LD between rs11959427 and
rs1042714 (D' = 1, r2 = 0.82) is similar to a previous report
by Japanese researchers [6], but much stronger than that
in the Polish study [7].
All the fifteen SNPs were subsequently included in the tag
SNP selection, and ten tag SNPs were selected and geno-
typed in the case-control collection. Allele and genotype
frequencies for these tag SNPs are shown in Table 2. All
tag SNPs genotypes in cases and controls conformed to
Hardy-Weinberg equilibrium (P > 0.001). Genotype dis-
tributions and allele frequencies of the ten tag SNPs in
ADRB2 were not significantly different between the GD
group and the control group (Table 2). When under the
assumption of dominant and recessive model, all the tag
SNPs failed to show associations with GD either (data not
shown here). Since the association of rs1042714 with GD
was stronger in the patients without symptoms of GO in
the Polish study[7], we also compared the allele and gen-
otype frequencies of rs1042714 in GD subjects with or
without GO to controls, and observed no difference
existed (Table 3). No blocks were detected based on the
ten tag SNPs. To explore the associations of haplotype
rs11959427/rs1042713/rs1042714 (-367T/+46A/+79C)
with GD as previously reported[7], we inferred the haplo-
types based on rs1042713 and rs1042714, since
rs11959427 captured by rs1042714 at r2 ≥ 0.8 were not
directly genotyped in our case-control collection. Three
common haplotypes were observed and none of them
showed statistically significant association with GD
(Table 4).BMC Medical Genetics 2009, 10:26 http://www.biomedcentral.com/1471-2350/10/26
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A meta-analysis for rs1042714 was conducted combining
the initial findings from the Polish populations, the data
set from the study of WTCCC et al. and the result of
present study, including a total of 1,728 GD patients and
2,491 control samples. The forest plots for the allele
model are shown in Figure 2. The p-value for Q-test is just
above the significance level (P = 0.12, Figure 2A), whereas
the I2 statistic suggested there was significant heterogene-
ity among the studies (I2 = 53.1%, Figure 2A). Since only
three studies were included in our meta-analysis, we chose
the result of I2 statistic as measurement of heterogeneity.
Then the pooled OR was calculated by random effects
approaches using DerSimonian and Laird methods[20].
The pooled OR was 1.13 but the confidence interval
spanned unity (95% CI, 0.95 to 1.36), which indicated
the combined data did not show significant association
for rs1042714 with GD. A sensitivity analysis showed that
the present study in Chinese population was the main
cause of the heterogeneity. When only the two European
studies (including 1300 cases and 1801 controls) were
combined, the heterogeneity was no longer significant (I2
= 5.9%, Figure 2B), and the result demonstrated signifi-
cant association by fixed effect (OR = 1.18, 95% CI, 1.06
to 1.32; P = 0.002, Figure 2B).
Discussion
We have performed a comprehensive study investigating
association of GD susceptibility with the ADRB2 variants
and failed to replicate association in Chinese population.
However, meta-analysis revealed that rs1042714 was sig-
nificantly associated with GD in Caucasian population.
Genetic association studies of GD applied to other non-
MHC candidate genes have also led to encouraging yet
somewhat inconsistent findings in recent years. Several
reasons may explain these inconsistent findings, includ-
ing allelic heterogeneity, true variation in disease associa-
tion between populations, modifying genetic and/or
environmental factors, statistically underpowered small
sample sizes, and a low prior probability of obtaining a
true result[21]. The most parsimonious explanation for
the lack of replication of initial ADRB2 association results
in our study would be variation in disease association
between populations and relatively small sample size.
It has long been noted that the MAF of rs1042714 locus
varies significantly among the major populations around
the world[5,22]. The minor allele of rs1042714 loci is
much more common in Caucasians than in Africans and
Asians according to the previous reports and Hapmap
data[5,22]. Xie et al [22]and Chang et al [23] observed that
the MAF of rs1042714 locus was 7.2% among 104 healthy
Chinese and 7.7% among 260 nondiabetic Chinese
respectively. The Hapmap data revealed the MAF of
rs1042714 locus was 12.2% among 45 Chinese. In our
study, the MAF of rs1042714 locus among the 690
healthy controls was 7.2%, consistent with the previous
report. In the previous reports of Jazdzewski K et al in
Polish population[7] and WTCCC et al in UK popula-
tion[8], carriers of the minor allele G were present less fre-
quently in the patient groups (38% and 43% respectively)
than in the control groups (45% and 46% respectively),
whereas in our data of Chinese population, the propor-
tion of minor allele G carriers was larger in cases (8%)
than in controls (7%). The trend of rs1042714 allele effect
in cases and controls was substantially different in the two
populations, which was also reflected by the OR value in
the meta-analysis (less or greater than 1, Figure 2A). The
allelic heterogeneity and opposite effect directions might
indicate variations in disease associations between popu-
lations.
Table 1: Fifteen SNPs in the ADRB2 gene identified from 24 GD patients and 24 control subjects
Rs number Position in ADRB2 Chromosome position Alleles HWpval MAF
rs17108803 - 839 148185749 T:G 1.00 0.032
rs12654778 - 654 148185934 G:A 0.13 0.415
rs11168070 - 468 148186120 C:G 1.00 0.062
rs11959427 - 367 148186221 T:C 1.00 0.062
-332 - 332 148186256 G:A 1.00 0.042
rs1042711 - 47 148186541 T:C 1.00 0.052
rs1801704 - 20 148186568 T:C 1.00 0.052
rs1042713 + 46 148186633 A:G 0.88 0.365
rs1042714 + 79 148186666 C:G 1.00 0.052
rs1042717 + 252 148186839 G:A 0.13 0.302
rs1042718 + 523 148187110 C:A 0.13 0.302
rs1042719 + 1053 148187640 G:C 0.60 0.389
rs3730182 + 1179 148187766 T:C 1.00 0.011
rs1042720 + 1239 148187826 A:G 0.58 0.352
SNP positions in the ADRB2 gene were numbered upstream (+) or downstream (-) from the ADRB2 transcription initiation site. Chromosome 
positions were referred to the sequence of NCBI database (built 35). SNP, single nucleotide polymorphism; Hwpval, Hardy-Weinberg equilibrium p 
value; MAF, minor allele frequency.BMC Medical Genetics 2009, 10:26 http://www.biomedcentral.com/1471-2350/10/26
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Linkage disequilibrium (LD) plots of the fifteen SNPs in ADRB2 identified from 48 subjects Figure 1
Linkage disequilibrium (LD) plots of the fifteen SNPs in ADRB2 identified from 48 subjects. We constructed the 
plots with the Haploview program [15], and r2 (×100) values were depicted in the diamonds. Blocks were determined using the 
default method of Gabriel et al [16].
Table 2: Association analysis of the ten tag SNPs in GD patients and control subjects
Allele Genotype of case Genotype of control Allele comparison Genotype comparison
Rs number 1/2 11 12 22 11 12 22 OR (95% CI) P value P value
rs2053044 G/A 220 167 32 375 251 52 0.932(0.768–1.131) 0.48 0.63
rs17108803 T/G 390 33 2 596 74 4 1.420(0.960–2.120) 0.08 0.21
rs12654778 G/A 161 196 68 254 316 112 1.022(0.858–1.219) 0.80 0.97
-332 G/A 410 15 1 645 28 0 1.043(0.568–1.918) 0.89 0.41
rs1042713 A/G 170 179 76 248 301 123 1.076(0.903–1.283) 0.41 0.58
rs1042714 C/G 358 63 3 592 88 5 0.870(0.631–1.199) 0.39 0.64
rs1042717 A/G 199 168 45 312 276 83 1.077(0.894–1.298) 0.43 0.73
rs1042719 G/C 137 216 66 213 318 139 1.128(0.947–1.343) 0.18 0.11
rs3730182 T/C 401 18 0 647 22 1 0.831(0.448–1.540) 0.56 0.64
rs1042720 A/G 155 208 56 280 293 94 0.913(0.763–1.091) 0.32 0.17BMC Medical Genetics 2009, 10:26 http://www.biomedcentral.com/1471-2350/10/26
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Genetic heterogeneity across populations had previously
been reported in GD and other polygenic autoimmune
diseases, such as in the case of SUMO4 gene association
with type 1 diabetes, GD, or rheumatoid arthritis (RA)
[24-33]. SUMO4 gene was suggested as a general autoim-
munity locus in the Asian population, associations with
type 1 diabetes, GD and RA have been reported[27,31-
33]. In contrast to the consistent association observed in
the Asian populations, no evidence of SUMO4 association
with susceptibility to type 1 diabetes, GD and RA was
found from several studies in European descent[26,28-
30]. One study did show SUMO4 was associated with
T1D in association with high risk HLADR3 and DR4 gen-
otypes in Swedish patients. But SUMO4 by itself was not
associated with the disease[34]. Interestingly, a tendency
for an opposite association was reported in type 1 diabetes
of British subjects[25].
The major limitation of our case-control study was that
the sample size was not very compelling. Sample size in
thousands of subjects might be more sufficient to detect
small genetic effects. However, positive association was
reported from analysis of 300 GD patients and 301 con-
trol samples in Polish population, and positive signal was
also found from the GWA screen of 1,000 GD patients
and 1,500 control samples in UK population[7,8]. This
prompted us to investigate the potential association
between ADRB2 and GD in fair number of well-defined
cases and controls (428 GD cases and 690 controls) in
Chinese population. Assuming a frequency of the risk
allele of 0.075, our study in 1,118 subjects had only 70%
power to detect the OR of 1.5 for rs1042714 with a signif-
icance level of 0.05. We sought to increase the effective
sample size and statistical power by meta-analysis and to
draw a more compelling result, but heterogeneity was
found to exist between European studies and our study,
and the data involved in ADRB2 association with GD in
Chinese and Caucasian populations must be analyzed
separately. The possibility that SNPs in ADRB2 may influ-
ence the disease risk modestly in Chinese population can-
not be excluded completely. Further accumulation of
samples would be needed for ascertainment. The overall
sample size included in the meta-analysis was relative
large (3101 Caucasian individuals) and this meta-analysis
provided an up-to-date summary of the association anal-
ysis between ADRB2 and GD. However, the number of
published studies available for meta-analysis was small,
which made our analysis more prone to publication bias.
Thus, it seems a little premature to draw conclusions that
ADRB2 is associated with GD susceptibility in Caucasian
populations.
A GD linkage locus had been mapped to chromosome
5q31-33 in Asian population in two GD genome screen
studies [2,4], but not detected in a Caucasian popula-
tion[35]. The genome wide association study in Cauca-
sians revealed some positive signal in this region[8], albeit
not as strong as other loci. Our meta-analysis showed
association of the ADRB2 variation with GD in Cauca-
sians, which provided new evidence for the presence of
GD susceptibility genes in 5q31-33. Much effort has been
spent in exploring the associated genes and/or the causal
allele(s) of Crohn disease[36,37] and rheumatoid arthri-
tis[38] located on the chromosome region of 5q31-33,
and great progress has been made. However, no con-
firmed GD association genes have been identified in this
region so far. Of note, different autoimmune diseases may
share similar genetic etiologies and susceptibility alleles;
therefore, the data sets from Crohn disease and rheuma-
toid arthritis studies will be helpful in further clarifying
the variant accounted for susceptibility to GD in this
region. A more comprehensive analysis of chromosome
5q31-33, including a wider range of SNPs in ADRB2 and
neighboring genes in a large, well matched dataset, is
required to determine whether a causal variant within any
candidates in this linkage region confers susceptibility to
GD.
Conclusion
We systematically studied the association of the ADRB2
gene by a case-control analysis using tag SNPs and a meta-
Table 3: Association analysis of the rs1042714 polymorphism in control subjects and GD patients with or without GO.
Genotype Allele comparison Genotype comparison
CC CG GG OR (95% CI) P value P value
Control 592 88 5
GO (-) 248 45 2 1.18(0.82–1.68) 0.38 0.60
GO (+) 110 18 1 1.09(0.66–1.80) 0.73 0.94
Table 4: Estimated frequencies of the haplotypes inferred from 
rs1042713 and rs1042714 in GD patients and controls
Haplotype Frequency (%) P value
rs1042713, rs1042714 Case Control
AC 0.584 0.584 0.996
GC 0.336 0.344 0.682
GG 0.080 0.072 0.482BMC Medical Genetics 2009, 10:26 http://www.biomedcentral.com/1471-2350/10/26
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analysis. The case-control study did not support ADRB2 as
a GD susceptibility gene in Chinese population, but our
meta-analysis provided strong evidence of a positive asso-
ciation of the ADRB2 SNP rs1042714 with GD in Cauca-
sians. More studies with large sample size in Chinese and
other populations are needed before solid conclusions
about the association could be made.
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